

EUROPEAN PSYCHIATRY

THE JOURNAL OF THE ASSOCIATION OF EUROPEAN PSYCHIATRISTS

New ♦ *an increased periodicity (8 issues per year)*
in ♦ *supplements devoted to specific symposia*
1995 ♦ *indexed in Current Contents*

Editors	Co-Editors	Deputy Editors
C Ballus Barcelona, Spain	M Maj Naples, Italy	P Boyer Paris, France
JD Guelfi Paris, France	CB Pull, Luxembourg	Y Lecrubier Paris, France
H Heimann Tübingen, Germany	M Ackenheil Munich, Germany	
R Murray London, United Kingdom	P Bech Copenhagen, Denmark	

Indexed in

Biological Abstracts/Biosis, CNRS/Pascal, Current Contents/Clinical Medicine and Social & Behavioural Sciences, Excerpta Medica/EMbase, Psychological Abstracts, Research Alert, SciSearch

Subscribe today!

by phone
(1) 45 58 90 67

by fax
(1) 45 58 94 24

Since 1991, *European Psychiatry* has been the official journal of the Association of European Psychiatrists (AEP).

European Psychiatry presents the results of original research relative to those numerous diverse fields currently of interest to psychiatrists: psychopathology, nosography, chemotherapy, psychotherapy, clinical methodology, biological disorders and mental pathology, psychophysiology, neuropsychophysiology, relative to therapeutics, clinical and basic research as well as animal behaviour.

This wide scope is aimed at encouraging the exchange of ideas and research within Europe and establishing within the international psychiatric community an improved level of scientific communication.

European Psychiatry endeavours to publish not only high scientific level original articles, short communications, editorials, letters to the editor but also AEP newsletters, book reviews, information on new regulations in Europe and a conference calendar.

Submission of manuscripts

should be made to one of the Editors indicated above. Addresses of the Editors and Instructions to Authors are available upon request from the secretariat (*European Psychiatry*, Hôpital de la Salpêtrière, Pavillon Clérambault, 47, bd de l'Hôpital, 75651 Paris Cedex 13, France. Fax no: 33 (1) 45 85 28 00)

EUROPEAN PSYCHIATRY – 1995 – Volume 10 in 8 issues – ISSN 0924-9338

Please, send to:



PUBLICATIONS ELSEVIER

A division of
ÉDITIONS SCIENTIFIQUES ET MÉDICALES ELSEVIER SAS
141, rue de Javel
75747 Paris Cedex 15, France

A member of the Reed Elsevier Medical group

in North America:
Elsevier Science Inc.

655 Avenue of the Americas
New York, NY 10010, USA

Please send your order to the Paris address

Please,

- enter my 1995 subscription to *European Psychiatry*
France: 1780 FF – EU (with VAT registration no _____) and rest of the world: 1995 FF
EU (individuals): 2037 FF – North, Central and South America: 294 US \$
Student (copy of the student card requested) France: 1068 FF – Rest of the world: 1222 FF
All price include postage and handling

- send me a free sample copy
- find my check enclosed payable to
Éditions scientifiques et médicales Elsevier
- debit my credit card (CB, MasterCard or Visa)
- No Expires
- send me an invoice

A special rate is available to the members of the Association of European Psychiatrists

Signature: _____

NAME _____


TITLE _____ SPECIALITY _____ FUNCTION _____

ADDRESS PROFESSIONAL PERSONAL _____

POSTAL CODE/CITY/STATE _____

COUNTRY _____

IMOVANE, 24 hours in harmony.



International multi-centre study confirms that Imovane improves the Quality of Life.

This study was conducted in 5 different European countries, in 86 different locations and included 458 patients.

The main objective was to study patients' quality of life during two weeks of continuous therapy with IMOVANE, which were then followed by a further six weeks of therapy on request.

Measurements recorded for four different quality of life criteria (*sleep, physical condition, daily activity, social life*) were all significantly in favour of IMOVANE.

24 hours in harmony is what IMOVANE promises. This comes as a result of the interactions between the separate measurements achieved in this study. When a patient sleeps better, his sleep will be more restorative; he will awake refreshed, and his daily activities and social life will be improved.



Presentation : White elliptical tablets containing 7.5 mg zopiclone. The tablets also contain lactose. **Pharmacology** : Zopiclone is a non-benzodiazepine hypnotic, a member of the cyclopyrrolone group of compounds which is structurally unrelated to existing hypnotics and tranquilisers. **Indications** : for short term treatment of insomnia which is debilitating or causing severe distress for the patient. A course of treatment should not be longer than 4 weeks. **Dosage and Administration** : Adults : One 7.5 mg tablet shortly before retiring. This may be increased to two tablets for patients who do not respond to the lower dose. Elderly : A lower dose of 3.75 mg zopiclone is recommended initially. The dosage subsequently may be increased if clinically necessary. Children : Not recommended. **Contraindications** :

marked personality disorders. **Withdrawal** : Withdrawal effects unlikely, although all patients should be monitored. **Interactions** : Alcohol, CNS depressants, tricyclic antidepressants. **Adverse effects** : Most frequently, mild bitter or metallic after-taste, mild gastrointestinal disturbances. Occasionally drowsiness on waking, dizziness, light-headaches and uncoordination. Although residual effects are rare, patients should not drive or operate machinery until it is established that performance is unimpaired. Psychological and behavioural disturbances and allergic manifestations such as urticaria or rash have been reported. **Legal Category** : POM. **Pharmaceutical Precautions** : Protect from light. Store in a dry place below 30°C.

